Novavax (NVAX) provides a positive report from the Phase I trial of what would be the first...

|By:, SA News Editor

Novavax (NVAX) provides a positive report from the Phase I trial of what would be the first vaccine for respiratory syncytial virus (RSV), which causes pneumonia, as well as bronchiolitis in babies. Shares -3.5% but they've been rising since the middle of June. (PR)